Click on headlines below to download research

Continued positive responses in ALICE trial
Oryzon Genomics | 10/06/2022

Oryzon presented a 42-month update of its ongoing Phase IIa ALICE trial for the treatment of acute myeloid leukaemia (AML) in newly diagnosed elderly/unfit…

FRIDA funding and orphan drug designation
Oryzon Genomics | 09/06/2022

Oryzon Genomics has been awarded a $2m public grant to support its ongoing Phase Ib FRIDA clinical study. This follows recent FDA approval of its investigational…

Planning iadademstat’s path to market
Oryzon Genomics | 09/02/2022

Oryzon is making progress with its two epigenetic drugs, iadademstat for oncology and vafidemstat for CNS indications (both are lysine-specific demethylase…

Termination of coverage
Termination of coverage | 01/07/2021

Edison Investment Research is terminating coverage on Codere (CDR), Fidelity Asian Values (FAS), Fidelity China Special Situations (FCSS), Fidelity European…

Large response benefit consistent in ALICE trial
Oryzon Genomics | 15/06/2021

On 11 June 2021, Oryzon presented an updated set of data from the Phase IIa ALICE trial in acute myeloid leukaemia (AML) at the virtual Congress of the…

Termination of coverage
Termination of coverage | 30/03/2021

Edison Investment Research is terminating coverage on EJF Investments (EJFI), ROVI Laboratorios Farmaceuticos (ROVI) and SDX Energy (SDX). Please note…

2021: A pinnacle year
Laboratorios Farmacéuticos ROVI | 10/03/2021

Laboratorios Farmacéuticos ROVI (ROVI) has reported a strong set of FY20 results, with all pillars of the business contributing to revenue growth…

Response rates consistently high in ALICE trial
Oryzon Genomics | 11/12/2020

Oryzon presented an updated set of data from the Phase IIa ALICE trial in acute myeloid leukaemia (AML) at this year’s virtual ASH conference (5–8…